 |
|
Gene variant linked to risk of stroke and heart attack for those on Plavix
August 26, 2009NIGMS media availability
WHAT: A new study reports that a gene variant carried by about a third of the population plays a major role in this group's response to an anti-clotting medicine, clopidogrel (Plavix). People with the variant produce a defective version of the CYP2C19 enzyme and are less able to activate the drug.
One of the world's best-selling medicines, Plavix prevents blood clots in people with heart disease by keeping platelets from sticking together. But about 30 percent of people respond poorly to the drug and are at increased risk for dangerous events like strokes and heart attacks.
By performing a sophisticated method called a genome-wide association study in two distinct populations, Pennsylvania Amish and residents of urban Baltimore, the researchers found that a common variant of the CYP2C19 gene is a key determinant of how people respond to Plavix. The CYP2C19 enzyme chemically modifies the drug inside the body, converting it to the active form.
NIH/National Institute of General Medical Sciences
By performing a sophisticated method called a genome-wide association study in two distinct populations, Pennsylvania Amish and residents of urban Baltimore, the researchers found that a common variant of the CYP2C19 gene is a key determinant of how people respond to Plavix. The CYP2C19 enzyme chemically modifies the drug inside the body, converting it to the active form.
NIH/National Institute of General Medical Sciences
Plavix Current Events and Plavix News RSSGlobal public health the focus of scientific conference
Counterfeit and adulterated food and drugs and advances in measurement science used to detect them emerged as key themes of the Annual Scientific Meeting (ASM) hosted by the U.S. Pharmacopeial (USP) Convention.
University of Maryland researchers identify gene variant linked to effectiveness of plavix
Researchers at the University of Maryland School of Medicine have identified a common gene variant carried by as many as a third of the general population that is believed to play a major role in determining why people do not respond to a popular anti-clotting medication, Plavix.
Study shows benefits of anti-clotting medications reduced by common heartburn drugs
The anti-clotting action of the medication clopidogrel (Plavix) can be compromised by common drugs for the treatment of heartburn and ulcers resulting in a roughly 50% increase in the combined risk of hospitalization for heart attack, stroke and other serious cardiovascular illnesses.
Johns Hopkins scientists discover what drives the development of a fatal form of malaria
Platelets - those tiny, unassuming cells that cause blood to clot and scabs to form when you cut yourself - play an important early role in promoting cerebral malaria, an often lethal complication that occurs mostly in children.
Still puzzling: Best care for the frail and elderly with coronary artery disease
A new study from Duke University Medical Center finds that patients treated solely with medications after suffering from chest pain, heart attack or coronary artery disease are more likely to die during the first year following their initial hospitalization.
Reducing Blockage Fails to Improve Access to the Bloodstream for Kidney Dialysis
Reducing early blockages in bloodstream access for kidney failure treatment does not increase the likelihood that the access will function adequately for long-term treatments, according to a study funded by the National Institutes of Health. Results were published May 14, 2008, in the Journal of the American Medical Association.
Fugitive cancer cells can be blocked by stopping blood cells that aid them
Cancer cells get a helping hand from platelets, specialized blood cells involved in clotting. Platelets shelter and feed tumor cells that stray into the bloodstream, making it easier for cancer to spread, or metastasize.
Study Finds Half of Patients Undergoing Cerebrovascular Stent Placement Respond Poorly to the Antiplatelet Drug Clopidogrel (Plavix)
A study by researchers at Rush University Medical Center, published in the February issue of the American Journal of Neuroradiology, finds that half of patients undergoing cerebrovascular stent placement did not respond well to clopidogrel. Clopidogrel (Plavix) and aspirin are medications routinely prescribed for 1-3 months following cerebrovascular stent placement to combat the risk of blood clots (stent-thrombosis) and reclosure of the artery (re-stenosis).
Researchers find deadly prescription drug effects 6 years before FDA
Northwestern University's Charles Bennett, M.D., is a super sleuth of potentially deadly prescription drug reactions.
Bare-metal stents are better for some heart patients
While drug-eluting stents are effective in keeping open diseased heart arteries, they should not be used for patients who need to have non-cardiac surgery a short time after an interventional heart procedure.
More Plavix Current Events and Plavix News Articles
|
Use caution if taking a proton pump inhibitor and Plavix: the two-drug combo may cause dangerous side effects.(RISK REDUCTION): An article from: Women's Health Advisor by Unavailable (Author) This digital document is an article from Women's Health Advisor, published by Belvoir Media Group, LLC on June 1, 2009. The length of the article is 431 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: Use caution if taking a proton pump inhibitor and Plavix: the two-drug combo may cause dangerous side effects.(RISK REDUCTION) Author: Unavailable Publication: Women's Health Advisor (Magazine/Journal) Date: June 1, 2009 Publisher: Belvoir Media Group, LLC Volume: 13 Issue: 6 Page: 6(2) Distributed by Gale, a part of Cengage... | |
 |
Olympian Labs Clinical Resveratrol, 150mg by Olympian Labs Resveratrol is a naturally occurring phytoalexin. Phytoalexins are chemical substances produced by plants as a defense against environmental stresses and infection by pathogenic microorganisms, such as fungi. Studies suggest that resveratrol demonstrates potent antioxidant activity and may be associated with a reduced risk of cancer. Resveratrol may also be cardioprotective due to its ability to inhibit the oxidation of low-density lipoproteins (LDL) and inhibit platelet aggregation. Warning Signals: Check with your doctor before you take any dietary supplement, including vitamins and minerals. If your doctor starts you on a supplement, watch for warning signals that could indicate problems: stomach discomfort, pain, headache, rashes, or even vague symptoms like tiredness,... |
 |
Plavix - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References by ICON Health Publications (Author) In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading." Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing.This book was created for medical professionals, students, and members of the general public who want to conduct medical research using the most advanced tools available and spending the least amount of time doing so. |
|
Clopidogrel plus aspirin cut ischemic events 27%. (Dual Therapy Post Angioplasty).(Plavix): An article from: Family Practice News by Bruce Jancin (Author) This digital document is an article from Family Practice News, published by International Medical News Group on January 1, 2003. The length of the article is 621 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Clopidogrel plus aspirin cut ischemic events 27%. (Dual Therapy Post Angioplasty).(Plavix) Author: Bruce Jancin Publication: Family Practice News (Magazine/Journal) Date: January 1, 2003 Publisher: International Medical News Group Volume: 33 Issue: 1 Page: 17(1) Article Type: Product/Service Evaluation Distributed by Thomson... | |
|
Plavix, emend.(New & Approved): An article from: Skin & Allergy News by Elizabeth Mechcatie (Author) This digital document is an article from Skin & Allergy News, published by Thomson Gale on November 1, 2006. The length of the article is 866 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Plavix, emend.(New & Approved) Author: Elizabeth Mechcatie Publication: Skin & Allergy News (Magazine/Journal) Date: November 1, 2006 Publisher: Thomson Gale Volume: 37 Issue: 11 Page: 52(1) Distributed by Thomson... | |
|
Lawsuits question safety and efficacy of Plavix.: An article from: Trial by Allison Torres Burtka (Author) This digital document is an article from Trial, published by Thomson Gale on March 1, 2007. The length of the article is 917 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Lawsuits question safety and efficacy of Plavix. Author: Allison Torres Burtka Publication: Trial (Magazine/Journal) Date: March 1, 2007 Publisher: Thomson Gale Volume: 43 Issue: 3 Page: 74(2) Distributed by Thomson Gale | |
|
Peripheral Arterial Disease (Are You at Risk for Heart Attack or Stroke?) by Plavix (Author) Peripheral Arterial Disease: Are you at Risk for Heart Attack or Stroke? Patients with peripheral arterial disease are six times more likely to die from cardiovascular disease within 10 years. Covers issues as; Normal, Early Stage PAD, Advanced Stage PAD, Antiplatelet Therapy and Treating PAD. 1999 Edition! | |
|
St. John's wort reverses clopidogrel resistance.(Rx): An article from: Internal Medicine News by Bruce Jancin (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on May 15, 2005. The length of the article is 473 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: St. John's wort reverses clopidogrel resistance.(Rx) Author: Bruce Jancin Publication: Internal Medicine News (Magazine/Journal) Date: May 15, 2005 Publisher: International Medical News Group Volume: 38 Issue: 10 Page: 47(1) Distributed by Thomson... | |
|
Early clopidogrel can improve MI outcome: benefit seen in patients with ST-segment elevation who undergo percutaneous coronary interventions.(Cardiovascular ... An article from: Internal Medicine News by Mitchel L. Zoler (Author) This digital document is an article from Internal Medicine News, published by Thomson Gale on November 15, 2005. The length of the article is 907 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Early clopidogrel can improve MI outcome: benefit seen in patients with ST-segment elevation who undergo percutaneous coronary interventions.(Cardiovascular Medicine) Author: Mitchel L. Zoler Publication: Internal Medicine News (Magazine/Journal) Date: November 15, 2005 Publisher: Thomson Gale Volume: 38 Issue: 22 Page: 50(1) Distributed by Thomson... | |
|
CHARISMA results create confusion, anxiety about Clopidogrel.(News)(Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, ... An article from: Family Practice News by Bruce Jancin (Author) This digital document is an article from Family Practice News, published by Thomson Gale on April 15, 2006. The length of the article is 464 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: CHARISMA results create confusion, anxiety about Clopidogrel.(News)(Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial) Author: Bruce Jancin Publication: Family Practice News (Magazine/Journal) Date: April 15, 2006 Publisher: Thomson Gale Volume: 36 Issue: 8 Page: 8(1) Distributed by Thomson... |
| © 2009 BrightSurf.com |